Jinri Pharmaceutical

Jinri Biotech is a clinical-stage biopharmaceutical company based in Shanghai, China, dedicated to the discovery and development of innovative small molecule drugs for oncology. The company focuses on targeting the RAS/MAPK signaling pathway, which is a major driver in various human cancers. Utilizing a structure-based drug discovery platform, Jinri Biotech has developed a pipeline of potent and selective inhibitors. Its lead candidate, JR-2001, is a KRAS G12C inhibitor currently in Phase 1 clinical trials for advanced solid tumors. The company's broader pipeline includes programs targeting KRAS G12D, SOS1, and SHP2, aiming to provide new therapeutic options for patients with genetically defined cancers.